Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KROMEK GROUP PLC Director's Dealing 2016

Mar 14, 2016

7753_dirs_2016-03-14_da341655-1bf9-4da4-ab11-e22095473084.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9208R

Kromek Group PLC

14 March 2016

14 March 2016

Kromek Group plc

("Kromek" or the "Company")

Director Share Purchase

Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces that, on 11 March 2016, it received notification that Mr. Lawrence Kinet, a Non-Executive Director of the Company, purchased 120,000 Ordinary Shares of 1 pence each ("Ordinary Shares") in the Company, between 9 March 2016 and 11 March 2016, at a price of 32.25 pence per share.

Following the purchase, Mr. Kinet has an interest in 150,000 Ordinary Shares representing 0.1% of the entire current issued share capital of the Company.

Enquiries

Kromek Group plc
Arnab Basu, CEO

Derek Bulmer, CFO
+44 (0)1740 626 060
Cenkos Securities plc
Bobbie Hilliam (NOMAD)

Julian Morse (Sales)
+44 (0)20 7397 8900
Luther Pendragon Ltd
Harry Chathli, Claire Norbury, Alexis Gore +44 (0)20 7618 9100

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT").  Using its core CZT technology, Kromek designs develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEAEDDFSNKEAF